查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439242

神经调节设备 - 全球市场考量、竞争格局、市场预测 (2030)

Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: 按订单生产 | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

全球神经调节设备市场规模预计到 2023 年将达到 57.1 亿美元，到 2030 年将达到 95.6 亿美元，2024-2030 年预测期间复合年增长率为 8.95%。对神经调节设备的需求主要由老年人口的增长和神经系统疾病患病率的增加、设备扩展到其他慢性适应症和目标用途、产品组合的技术进步以及患者对神经系统疾病的需求不断增加所推动。部分原因是政府加大力度提高意识。

神经调节设备市场动态

神经系统疾病是主要影响中枢和周边神经系统的疾病，包括脑、脊髓、脑神经、週边神经、神经根、自主神经系统、神经肌肉接头和肌肉。根据世界卫生组织（WHO）2023年提供的数据，全球约有5,000万人患有癫痫症，使其成为2019年全球最常见的神经系统疾病之一。大约 80% 的癫痫患者生活在低收入和中等收入国家。

根据世界卫生组织2023年发布的数据，约有5,500万人患有失智症，每年新增病例近1,000万例。

神经调节是一种直接影响神经的技术。它透过直接向目标区域施加电刺激来改变（或调节）神经活动。神经调节装置将电极连接到大脑、脊髓和周边神经，以治疗和缓解各种神经系统疾病的症状，例如癫痫、偏头痛和帕金森氏症。因此，全球各种神经系统疾病的日益普及可能成为全球神经调节设备市场的成长动力。

此外，神经调节装置几乎可以治疗任何疾病或病症，从头痛到震颤、脊髓损伤、尿失禁等。凭藉如此广泛的治疗范围和生物技术的持续重大改进，神经调节在预测期内被定位为高成长产业也就不足为奇了。除了慢性疼痛治疗之外，神经调节还有许多应用，包括帕金森氏症的深部脑部刺激（DBS）疗法、针对骨盆腔疾病和尿失禁的荐神经刺激疗法。例如，Medtronic的ENTERRA II NEUROSTIMULATOR是一种胃神经刺激装置，可产生微弱的电脉衝，用于电刺激胃，以治疗胃轻瘫引起的慢性、顽固性噁心和呕吐。

因此，扩大用于其他慢性适应症和目标应用的设备的使用预计也将推动全球神经调节设备市场。

然而，这些设备的高成本以及低诊断和治疗率等某些因素可能会限制神经调节设备市场的成长。

神经调节设备市场细分分析

在神经调节设备产品领域，脊髓刺激设备在预测期内将占据很大的市场。这是由于患有慢性疼痛、脊椎手术后疼痛症候群和复杂区域疼痛症候群 (CRPS) 的患者数量不断增加。例如，根据CDC（2020）的数据，2019年，20.4%的成年人患有慢性疼痛，7.4%的成年人患有经常限制其生活和工作活动的慢性疼痛（称为高负担慢性疼痛） . ，两者都随着年龄的增长而增加，并且在65 岁及以上的成年人中最高。

此外，最近推出的技术先进的脊髓刺激设备（配有可充电电池和无线远端技术）的产品也促进了该领域的成长。例如，Boston Scientific Corporation于 2020 年在欧洲推出了脊髓刺激设备 (SCS) 系统的 WaveWriter Alpha□ 产品组合。该产品组合由四个支援MRI 条件的蓝牙植入式脉衝产生器(IPG) 组成，可提供患者友好型选项，包括可充电和不可充电选项以及可覆盖多个疼痛区域的波形。我们正在基于以下基础扩展个性化范围：需要。

该报告提供了全球神经调节设备市场的研究和分析，包括市场规模和预测、驱动因素和挑战以及公司和产品概况。

目录

第1章 神经调节装置介绍报告

第2章 神经调节设备的执行摘要

  • 调查范围
  • 市场概况
  • 竞争评估

第3章 监管分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第4章 神经调节设备市场关键因素分析

  • 神经调节设备市场的驱动因素
    • 老年人口增加及神经系统疾病盛行率增加
    • 该设备扩展到其他慢性疾病和针对性应用
    • 我们产品组合的技术进步
    • 政府加强提高患者对神经系统疾病的认识
  • 神经调节设备市场的限制与挑战
    • 设备和程序成本高
    • 复杂的监管审批场景
  • 神经调节设备的市场机会
    • 对非侵入式设备的需求不断增长
    • 发展中国家的市场成长机会

第5章 神经调节装置的波特五力分析

第6章 神经调节设备市场布局

  • 按类型
    • 侵入性的
    • 非侵入性
  • 按产品类型
    • 脊髓刺激装置
    • 迷走神经刺激装置
    • 脑深部电刺激装置
    • 荐神经刺激装置
    • 经颅磁刺激仪
    • 其他
  • 按用途
    • 疼痛管理
    • 神经系统疾病
    • 呼吸系统疾病
  • 按最终用户
    • 医院
    • 专科诊所
  • 按地区
    • 北美
    • 欧洲神经调节设备市场规模（2021-2030）
    • 亚太地区神经调节设备市场规模（2021-2030）
    • 其他地区神经调节设备市场规模（2021-2030）

第7章 神经调节设备公司及产品简介

  • Medtronic
  • Boston Scientific Corporation
  • Abbott
  • LivaNova
  • NeuroSigma
  • NEVRO CORP.
  • Synapse Biomedical Inc.
  • NeuroPace, Inc.
  • Bioventus
  • Soterix Medical Inc.
  • Helius Medical Technologies
  • Axonics, Inc.
  • MicroTransponder Inc.
  • electroCore, Inc.

第8章 KOL观点

第9章 专案方法

第10章 DelveInsight服务内容

第11章 关于 DelveInsight

第12章 免责声明与联络我们

Product Code: DIMDCL0029

Neuromodulation Devices Market By Type (Invasive and Non-Invasive), Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and Others), Application (Pain Management, Neurological Disorder, Respiratory Disorders, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography is expected to grow at a static CAGR forecast till 2030 due to Advances in Product Portfolio and Burgeoning Neurological Disorder Prevalence among the aging population

The global neuromodulation devices market was valued at USD 5.71 billion in 2023, growing at a CAGR of 8.95% during the forecast period from 2024 to 2030, to reach USD 9.56 billion by 2030. The demand for neuromodulation devices is primarily motivated by the increasing prevalence of neurological disorders coupled with the rising aging population, expansion of the devices to other chronic indications and target applications, technological advancement in the product portfolio, rising government initiatives to raise awareness among patient regarding neurological disorders, among others.

Neuromodulation Devices Market Dynamics:

Neurological disorders are diseases that affect the central and peripheral nervous system which primarily include the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscles. According to the data provided by the World Health Organization (WHO) 2023, approximately 50 million people across the globe were suffering from epilepsy, making it one of the most common neurological diseases globally in 2019. About 80% of people with epilepsy live in low- and middle-income countries.

As per the data provided by WHO 2023, about 55 million people are living with dementia, and there are nearly 10 million new cases every year.

Neuromodulation is a technique that directly acts on nerves. It changes (or modulates) nerve activity by delivering electrical stimulation directly to the target area. Neuromodulation devices involve applying electrodes to the brain, spinal cord, or peripheral nerves to treat or reduce the symptom of various neurological disorders such as epilepsy, migraine, and Parkinson's disease, among others. Therefore the rising prevalence of various neurological disorders across the globe could be a potential factor leading to the growth of the global neuromodulation devices market.

Moreover, neuromodulation devices treat almost all diseases or symptoms, from headaches to tremors, spinal cord injuries and urinary incontinence, and others. With such a wide range of treatments and significant continuous improvements in biotechnology, it is not surprising that neuromodulation is positioned as a high-growth industry during the forecasted period. In addition to treating chronic pain, there are many neuromodulation applications, such as deep brain stimulation (DBS) treatment for Parkinson's disease, sacral nerve stimulation for pelvic diseases, and urinary incontinence. For instance, ENTERRA II NEUROSTIMULATOR by Medtronic is a gastric neurostimulator that generates mild electrical pulses for gastric electrical stimulation to treat chronic, intractable nausea and vomiting due to gastroparesis.

Therefore, the expansion of device usage to other chronic indications and targeted applications is also anticipated to propel the global neuromodulation devices market.

However, certain factors such as the high cost of these devices and the lower rate of diagnosis and treatment are likely to impede the growth of the neuromodulation devices market.

Neuromodulation Devices Market Segment Analysis:

Neuromodulation Devices Market by Type (Invasive and Non-Invasive), Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and Others), Application (Pain Management, Neurological Disorder, Respiratory Disorders, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the neuromodulation devices product segment, spinal cord stimulators hold a significant market during the forecasted period. This is owing to the growing patient population suffering from chronic pain, failed back syndrome, and complex regional pain syndrome (CRPS). For instance, according to CDC 2020 data, in 2019, 20.4% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities (referred to as high-impact chronic pain) and both increased with age and were highest among adults aged 65 and over.

Moreover, recent product launches of technologically advanced spinal cord stimulators with rechargeable batteries and wireless remote techniques also contribute to segmental growth. For instance, in 2020, Boston Scientific Corporation launched the WaveWriter Alpha(TM) portfolio of Spinal Cord Stimulator (SCS) Systems in Europe. The portfolio consists of four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs), that offer expanded personalization based on patient needs, including rechargeable and non-rechargeable options, and access to waveforms that can cover multiple areas of pain.

In addition, emerging guidelines from the government for spinal cord stimulation therapy for the treatment of chronic pain and other indications are also anticipated to augment the market. For instance, in January 2019, National Institute for Health and Care Excellence (NICE) published guidelines and recommendations for Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.

Hence, all the mentioned factors are likely to fuel the segmental growth of the Neuromodulation Devices market during the forecasted period.

North America is expected to dominate the overall Neuromodulation Devices Market:

North America is expected to dominate the overall Neuromodulation Devices market during the forecast period. This domination is due to the increased healthcare expenditure along with the presence of a well-developed and advanced healthcare system in the region. Moreover, higher diagnosis and treatment rates and adequate reimbursement policies are the driving factors.

Further, In the United States, the presence of neuromodulation device companies in the market such as Abbott, Boston Scientific Corporation, and Medtronic, among others is likely to boost the market. Also, the growing prevalence of neurological disorders such as Parkinson's disease, epilepsy, migraine, and treatment-resistant depressive order is expected to bolster the market. For instance, as per the Parkinson's Foundation 2022 study, every year in the United States about 90,000 people are diagnosed with Parkinson's disease. Thus, rising cases of Parkinson's among other neurological disorders could be a significant factor for the neuromodulation devices market growth.

Moreover, an increase in product approval by FDA is also a driving factor for neuromodulation devices in the region. For instance, in June 2020, Medtronic received Food and Drug Administration (FDA) approval for the Percept(TM) PC Deep Brain Stimulation (DBS) system. BrainSense(TM) technology makes Percept the first and only DBS neurostimulation system with the ability to chronically capture and record brain signals while delivering therapy to patients with neurologic disorders associated with Parkinson's disease, essential tremor, dystonia, epilepsy, or obsessive-compulsive disorder (OCD).

Thus, the aforementioned factors are likely to upsurge the market for neuromodulation devices in the region.

Neuromodulation Devices Market Key Players:

Some of the key market players operating in the neuromodulation devices market include Medtronic,

Boston Scientific Corporation, Abbott, LivaNova, NeuroSigma, NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus., Soterix Medical Inc., and others.

Recent Developmental Activities in Neuromodulation Devices Market:

In March 2021, Axonics Modulation Technologies, Inc. entered into a strategic alliance with Micro Systems Technologies (MST) for the manufacture of a non-rechargeable implantable sacral neuromodulation device.

In March 2021, Helius Medical received the US FDA approval for Portable Neuromodulation Stimulator approval for short-term treatment of gait deficit due to multiple sclerosis.

In January 2021, Boston Scientific Corporation received FDA approval for its fourth-generation Vercise Genus Deep Brain Stimulation (DBS) System used to treat symptoms in patients with advanced Parkinson's disease.

Key Takes Away from the Neuromodulation Devices Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global neuromodulation devices market.

Various opportunities available for the other competitor in the neuromodulation devices market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for neuromodulation devices market growth in the coming future?

Target Audience who can be benefited from Neuromodulation Devices Market Report Study

Neuromodulation Devices providers

Research organizations and consulting companies

Neuromodulation Devices-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in Neuromodulation Devices

Various End-Users who want to know more about the neuromodulation devices market and the latest technological developments in the neuromodulation devices market.

Frequently Asked Questions for Neuromodulation Devices Market:

1. What are neuromodulation devices?

Neuromodulation devices, also known as neurostimulation devices involve the application of electrodes to the brain, the spinal cord, or peripheral nerves. These devices can increase or decrease the activity of the nervous system by generating necessary electrical stimulation.

2. What is the market for global neuromodulation devices?

The global neuromodulation devices market was valued at USD 5.71 billion in 2023, growing at a CAGR of 8.95% during the forecast period from 2024 to 2030, to reach USD 9.56 billion by 2030.

3. What are the drivers for global neuromodulation devices?

The major factors driving the demand for neuromodulation devices are the growing prevalence of neurological disorders coupled with the rising geriatric population, expanding device application in various other indications, and the launch of technically advanced products in the market.

4. What are the key players operating in global neuromodulation devices?

Some of the key market players operating in the neuromodulation devices market include Medtronic, Boston Scientific Corporation, Abbott, LivaNova, NeuroSigma, NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus., Soterix Medical Inc., and others

5. Which region has the highest share in the neuromodulation devices market?

North America is anticipated to dominate the overall Neuromodulation Devices market during the forecast period, 2024-2030 due to the increased healthcare expenditure along with the presence of a well-developed and advanced healthcare system in the region. Furthermore, rising diagnosis and treatment rates and adequate reimbursement policies also contribute to the highest regional share.

Table of Contents

1. Neuromodulation Devices Report Introduction

2. Neuromodulation Devices Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Neuromodulation Devices Market Key Factors Analysis

  • 4.1. Neuromodulation Devices Market Drivers
    • 4.1.1. Increasing prevalence of neurological disorder coupled with a rising aging population
    • 4.1.2. Expansion of the devices to other chronic indications and target application
    • 4.1.3. Technological advancement in the product portfolio
    • 4.1.4. Rising government initiative to raise awareness among patients regarding neurological disorders
  • 4.2. Neuromodulation Devices Market Restraints and Challenges
    • 4.2.1. High cost of the devices and procedure
    • 4.2.2. Complex regulatory approval scenario
  • 4.3. Neuromodulation Devices Market Opportunities
    • 4.3.1. Growing demand for non-invasive devices
    • 4.3.2. Market growth opportunities in developing nations

5. Neuromodulation Devices Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. Neuromodulation Devices Market layout

  • 6.1. By Type
    • 6.1.1. Invasive
    • 6.1.2. Non-invasive
  • 6.2. By Product Type
    • 6.2.1. Spinal Cord Stimulators
    • 6.2.2. Vagus Nerve Stimulators
    • 6.2.3. Deep Brain Stimulators
    • 6.2.4. Sacral Nerve Stimulators
    • 6.2.5. Transcranial Magnetic Stimulators
    • 6.2.6. Others
  • 6.3. By Application
    • 6.3.1. Pain Management
    • 6.3.2. Neurological disorder
    • 6.3.3. Respiratory disorder
    • 6.3.4. Others
  • 6.4. By End-User
    • 6.4.1. Hospitals
    • 6.4.2. Specialty Clinics
    • 6.4.3. Others
  • 6.5. By Geography
    • 6.5.1. North America
      • 6.5.1.1. United States Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.1.2. Canada Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.1.3. Mexico Neuromodulation Devices Market Size in USD million (2021-2030)
    • 6.5.2. Europe Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.2.1. France Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.2.2. Germany Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.2.3. United Kingdom Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.2.4. Italy Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.2.5. Spain Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.2.6. Rest of Europe Neuromodulation Devices Market Size in USD million (2021-2030)
    • 6.5.3. Asia-Pacific Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.3.1. China Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.3.2. Japan Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.3.3. India Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.3.4. Australia Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.3.5. South Korea Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.3.6. Rest of Asia-Pacific Neuromodulation Devices Market Size in USD million (2021-2030)
    • 6.5.4. Rest of the World (RoW) Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.4.1. Middle East Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.4.2. Africa Neuromodulation Devices Market Size in USD million (2021-2030)
      • 6.5.4.3. South America Neuromodulation Devices Market Size in USD million (2021-2030)

7. Neuromodulation Devices Company and Product Profiles

  • 7.1. Medtronic
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Boston Scientific Corporation
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Abbott
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. LivaNova
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. NeuroSigma
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. NEVRO CORP.
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Synapse Biomedical Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. NeuroPace, Inc.
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Bioventus
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. Soterix Medical Inc.
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Helius Medical Technologies
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. Axonics, Inc.
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. MicroTransponder Inc.
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. electroCore, Inc.
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy

8. KOL Views

9. Project Approach

10. DelveInsight Capabilities

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Neuromodulation Devices Market in Global (2021-2030)
  • Table 3: Neuromodulation Devices Market in Global by Type (2021-2030)
  • Table 4: Neuromodulation Devices Market in Global by Product (2021-2030)
  • Table 5: Neuromodulation Devices Market in Global by Application (2021-2030)
  • Table 6: Neuromodulation Devices Market in Global by End-User (2021-2030)
  • Table 7: Neuromodulation Devices Market in Global by Geography (2021-2030)
  • Table 8: Neuromodulation Devices Market in North America (2021-2030)
  • Table 9: Neuromodulation Devices Market in the US (2021-2030)
  • Table 10: Neuromodulation Devices Market in Canada (2021-2030)
  • Table 11: Neuromodulation Devices Market in Mexico (2021-2030)
  • Table 12: Neuromodulation Devices Market in Europe (2021-2030)
  • Table 13: Neuromodulation Devices Market in France (2021-2030)
  • Table 14: Neuromodulation Devices Market in Germany (2021-2030)
  • Table 15: Neuromodulation Devices Market in the United Kingdom (2021-2030)
  • Table 16: Neuromodulation Devices Market in Italy (2021-2030)
  • Table 17: Neuromodulation Devices Market in Spain (2021-2030)
  • Table 18: Neuromodulation Devices Market in Rest of Europe (2021-2030)
  • Table 19: Neuromodulation Devices Market in Asia-Pacific (2021-2030)
  • Table 20: Neuromodulation Devices Market in China (2021-2030)
  • Table 21: Neuromodulation Devices Market in Japan (2021-2030)
  • Table 22: Neuromodulation Devices Market in India (2021-2030)
  • Table 23: Neuromodulation Devices Market in Australia (2021-2030)
  • Table 24: Neuromodulation Devices Market in South Korea (2021-2030)
  • Table 25: Neuromodulation Devices Market in Rest of Asia-Pacific (2021-2030)
  • Table 26: Neuromodulation Devices Market in the Rest of the World (2021-2030)
  • Table 27: Neuromodulation Devices Market in the Middle East (2021-2030)
  • Table 28: Neuromodulation Devices Market in Africa (2021-2030)
  • Table 29: Neuromodulation Devices Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Neuromodulation Devices Market in Global (2021-2030)
  • Figure 3: Neuromodulation Devices Market in Global by Type (2021-2030)
  • Figure 4: Neuromodulation Devices Market in Global by Product (2021-2030)
  • Figure 5: Neuromodulation Devices Market in Global by Application (2021-2030)
  • Figure 6: Neuromodulation Devices Market in Global by End-User (2021-2030)
  • Figure 7: Neuromodulation Devices Market in Global by Geography (2021-2030)
  • Figure 8: Neuromodulation Devices Market in North America (2021-2030)
  • Figure 9: Neuromodulation Devices Market in the US (2021-2030)
  • Figure 10: Neuromodulation Devices Market in Canada (2021-2030)
  • Figure 11: Neuromodulation Devices Market in Mexico (2021-2030)
  • Figure 12: Neuromodulation Devices Market in Europe (2021-2030)
  • Figure 13: Neuromodulation Devices Market in France (2021-2030)
  • Figure 14: Neuromodulation Devices Market in Germany (2021-2030)
  • Figure 15: Neuromodulation Devices Market in the United Kingdom (2021-2030)
  • Figure 16: Neuromodulation Devices Market in Italy (2021-2030)
  • Figure 17: Neuromodulation Devices Market in Spain (2021-2030)
  • Figure 18: Neuromodulation Devices Market in Rest of Europe (2021-2030)
  • Figure 19: Neuromodulation Devices Market in Asia-Pacific (2021-2030)
  • Figure 20: Neuromodulation Devices Market in China (2021-2030)
  • Figure 21: Neuromodulation Devices Market in Japan (2021-2030)
  • Figure 22: Neuromodulation Devices Market in India (2021-2030)
  • Figure 23: Neuromodulation Devices Market in Australia (2021-2030)
  • Figure 24: Neuromodulation Devices Market in South Korea (2021-2030)
  • Figure 25: Neuromodulation Devices Market in Rest of Asia-Pacific (2021-2030)
  • Figure 26: Neuromodulation Devices Market in the Rest of the World (2021-2030)
  • Figure 27: Neuromodulation Devices Market in the Middle East (2021-2030)
  • Figure 28: Neuromodulation Devices Market in Africa (2021-2030)
  • Figure 29: Neuromodulation Devices Market in South America (2021-2030)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Market Opportunities
  • Figure 33: PORTER's Five Force Analysis